Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12967-020-02355-3 http://scihub22266oqcxt.onion/10.1186/s12967-020-02355-3 32370758!7200052!32370758     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Transl+Med 2020 ; 18 (1): 185 Nephropedia Template TP {{tp|p=32370758|t=2020. SARS-CoV-2 RNA polymerase as target for antiviral therapy |pdf=|usr=}}{{32370758}} gab.com Text SARS-CoV-2 RNA polymerase as target for antiviral therapy JO: J Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=32370758 #FOAvip A new human coronavirus named SARS-CoV-2 was identified in several cases of acute respiratory syndrome in Wuhan, China in December 2019. On March 11 2020, WHO declared the SARS-CoV-2 infection to be a pandemic, based on the involvement of 169 nations. Specific drugs for SARS-CoV-2 are obviously not available. Currently, drugs originally developed for other viruses or parasites are currently in clinical trials based on empiric data. In the quest of an effective antiviral drug, the most specific target for an RNA virus is the RNA-dependent RNA-polymerase (RdRp) which shows significant differences between positive-sense and negative-sense RNA viruses. An accurate evaluation of RdRps from different viruses may guide the development of new drugs or the repositioning of already approved antiviral drugs as treatment of SARS-CoV-2. This can accelerate the containment of the SARS-CoV-2 pandemic and, hopefully, of future pandemics due to other emerging zoonotic RNA viruses. Twit Text FOAVip SARS-CoV-2 RNA polymerase as target for antiviral therapy ????J Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=32370758 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32370758 #FOAvip English Wikipedia <ref>{{Cite pmid|32370758}}</ref> SARS-CoV-2 RNA polymerase as target for antiviral therapy #MMPMID32370758 Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM J Transl Med 2020[May]; 18 (1): 185 PMID32370758show ga A new human coronavirus named SARS-CoV-2 was identified in several cases of acute respiratory syndrome in Wuhan, China in December 2019. On March 11 2020, WHO declared the SARS-CoV-2 infection to be a pandemic, based on the involvement of 169 nations. Specific drugs for SARS-CoV-2 are obviously not available. Currently, drugs originally developed for other viruses or parasites are currently in clinical trials based on empiric data. In the quest of an effective antiviral drug, the most specific target for an RNA virus is the RNA-dependent RNA-polymerase (RdRp) which shows significant differences between positive-sense and negative-sense RNA viruses. An accurate evaluation of RdRps from different viruses may guide the development of new drugs or the repositioning of already approved antiviral drugs as treatment of SARS-CoV-2. This can accelerate the containment of the SARS-CoV-2 pandemic and, hopefully, of future pandemics due to other emerging zoonotic RNA viruses. |Amino Acid Sequence[MESH] |Antiviral Agents/*pharmacology[MESH] |Betacoronavirus/*drug effects/*enzymology/isolation & purification[MESH] |COVID-19[MESH] |Conserved Sequence[MESH] |Coronavirus Infections/*drug therapy/prevention & control/transmission/*virology[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Models, Molecular[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/*drug therapy/prevention & control/transmission/*virology[MESH] |RNA-Dependent RNA Polymerase/*antagonists & inhibitors/*chemistry/metabolism[MESH] |SARS-CoV-2[MESH] |Sequence Alignment[MESH] |Virus Replication/drug effects[MESH]SARS-CoV-2 RNA polymerase as target for antiviral therapy (epmc).pdf DeepDyve Pubget Overpricing